The NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional) from the National Institutes of Health (NIH) supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research relevant to drug abuse and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term avant-garde is used to describe highly innovative approaches that have the potential to be transformative. The proposed research should reflect approaches and ideas that are substantially different from those already being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities. Applications are open to researchers in the USA and worldwide. The grant provides 700,000 USD/year for up to 5 years. Funding opportunity number: PAR-23-269. Letters of intent are due on: July 15, 2023. Applications close on: August 15, 2023.